Crucial silences: When Accountability Met PFI and Finance Capital

During recent years, a wide spectrum of research has questioned whether public services/infrastructure procurement through private finance, as exemplified by the UK Private Finance Initiative (PFI), meets minimum standards of democratic accountability. While broadly agreeing with some of these arguments, this paper suggests that this debate is flawed on two grounds. Firstly, PFI is not about effective procurement, or even about a pragmatic choice of procurement mechanisms which can potentially compromise public involvement and input; rather it is about a process where the state creates new profit opportunities at a time when the international financial system is increasingly lacking in safe investment opportunities. Secondly, because of its primary function as investment opportunity, PFI, by its very nature, prioritises the risk-return criteria of private finance over the needs of the public sector client and its stakeholders. Using two case studies of recent PFI projects, the paper illustrates some of the mechanisms through which finance capital exercises control over the PFI procurement process. The paper concludes that recent proposals aimed at “reforming” or “democratising” PFI fail to recognise the objective constraints which this type of state-finance capital nexus imposes on political process.

Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas

Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma. Its effects are thought to be mediated mainly via its activity against ALK. Although MET genomic/protein expression status might conceivably affect crizotinib efficacy, this issue has hitherto not received attention in neuroblastomas.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity

Activation of the MET oncogenic pathway has been implicated in the development of aggressive cancers that are difficult to treat with current chemotherapies. This has led to an increased interest in developing novel therapies that target the MET pathway. However, most existing drug modalities are confounded by their inability to specifically target and/or antagonize this pathway. Anticalins, a novel class of monovalent small biologics, are hypothesized to be "fit for purpose" for developing highly specific and potent antagonists of cancer pathways. Here, we describe a monovalent full MET antagonist, PRS-110, displaying efficacy in both ligand-dependent and ligand-independent cancer models. PRS-110 specifically binds to MET with high affinity and blocks hepatocyte growth factor (HGF) interaction. Phosphorylation assays show that PRS-110 efficiently inhibits HGF-mediated signaling of MET receptor and has no agonistic activity. Confocal microscopy shows that PRS-110 results in the trafficking of MET to late endosomal/lysosomal compartments in the absence of HGF. In vivo administration of PRS-110 resulted in significant, dose-dependent tumor growth inhibition in ligand-dependent (U87-MG) and ligand-independent (Caki-1) xenograft models. Analysis of MET protein levels on xenograft biopsy samples show a significant reduction in total MET following therapy with PRS-110 supporting its ligand-independent mechanism of action. Taken together, these data indicate that the MET inhibitor PRS-110 has potentially broad anticancer activity that warrants evaluation in patients.

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

There are currently no approved targeted therapies for advanced KRAS mutant (KRASMT) colorectal cancer (CRC). Using a unique systems biology approach, we identified JAK1/2-dependent activation of STAT3 as the key mediator of resistance to MEK inhibitors in KRASMT CRC in vitro and in vivo. Further analyses identified acute increases in c-MET activity following treatment with MEK inhibitors in KRASMT CRC models, which was demonstrated to promote JAK1/2-STAT3-mediated resistance. Furthermore, activation of c-MET following MEK inhibition was found to be due to inhibition of the ERK-dependent metalloprotease ADAM17, which normally inhibits c-MET signaling by promoting shedding of its endogenous antagonist, soluble "decoy" MET. Most importantly, pharmacological blockade of this resistance pathway with either c-MET or JAK1/2 inhibitors synergistically increased MEK-inhibitor-induced apoptosis and growth inhibition in vitro and in vivo in KRASMT models, providing clear rationales for the clinical assessment of these combinations in KRASMT CRC patients.

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

Background: RAS is mutated (RASMT) in ~55% of mCRC, and phase III studies have shown that patients harbouring RAS mutations do not benefit from anti-EGFR MoAbs. In addition, ~50% of RAS Wild Type (RASWT) will not benefit from the addition of an EGFR MoAb to standard chemotherapy. Hence, novel treatment strategies are urgently needed for RASMT and > 50% of RASWT mCRC patients. c-MET is overexpressed in ~50-60%, amplified in ~2-3% and mutated in ~3-5% of mCRC. Recent preclinical studies have shown that c-MET is an important mediator of resistance to MEK inhibitors (i) in RASMT mCRC, and that combined MEKi/METi resulted in synergistic reduction in tumour growth in RASMT xenograft models (1). A number of recent studies have highlighted the role of c-MET in mediating primary/secondary resistance to anti-EGFR MoAbs in mCRC, suggesting that patient with RASWT tumours with aberrant c-MET (RASWT/c-MET+) may benefit from anti-c-MET targeted therapies (2). These preclinical data supported the further clinical evaluation of combined MEKi/METi treatment in RASMT and RASWT CRC patients with aberrant c-MET signalling (overexpression, amplification or mutation; RASWT/c-MET+). Methods: MErCuRIC1 is a phase I combination study of METi crizotinib with MEKi PD-0325901. The dose escalation phase, utilizing a rolling six design, recruits 12-24 patients with advanced solid tumours and aims to assess safety/toxicity of combination, recommended phase II (RPII) dose, pharmacokinetics (PK) and pharmacodynamics (PD) (pERK1/2 in PBMC and tumour; soluble c-MET). In the dose expansion phase an additional 30-42 RASMT and RASWT/c-MET mCRC patients with biopsiable disease will be treated at the RPII dose to further evaluate safety, PK, PD and treatment response. In the dose expansion phase additional biopsy and blood samples will be obtained to define mechanisms of response/resistance to crizotinib/PD-0325901 therapy. Enrolment into the dose escalation phase began in December 2014 with cohort 1 still ongoing. EudraCT registry number: 2014-000463-40. (1) Van Schaeybroeck S et al. Cell Reports 2014;7(6):1940-55; (2) Bardelli A et al. Cancer Discov 2013;3(6):658-73. Clinical trial information: 2014-000463-40.

Age-related prevalence and met need for correctable and uncorrectable near vision impairment in a multi-country study

Purpose: To estimate the prevalence, potential determinants, and proportion of met need for near vision impairment (NVI) correctable with refraction approximately 2 years after initial examination of a multi-country cohort. Design: Population-based, prospective cohort study. Participants: People aged ≥35 years examined at baseline in semi-rural (Shunyi) and urban (Guangzhou) sites in China; rural sites in Nepal (Kaski), India (Madurai), and Niger (Dosso); a semi-urban site (Durban) in South Africa; and an urban site (Los Angeles) in the United States. Methods: Near visual acuity (NVA) with and without current near correction was measured at 40 cm using a logarithm of the minimum angle of resolution near vision tumbling E chart. Participants with uncorrected binocular NVA ≤20/40 were tested with plus sphere lenses to obtain best-corrected binocular NVA. Main Outcome Measures: Prevalence of total NVI (defined as uncorrected NVA ≤20/40) and NVI correctable and uncorrectable to >20/40, and current spectacle wearing among those with bilateral NVA ≤20/63 improving to >20/40 with near correction (met need). Results: Among 13 671 baseline participants, 10 533 (77.2%) attended the follow-up examination. The prevalence of correctable NVI increased with age from 35 to 50-60 years and then decreased at all sites. Multiple logistic regression modeling suggested that correctable NVI was not associated with gender at any site, whereas more educated persons aged >54 years were associated with a higher prevalence of correctable NVI in Nepal and India. Although near vision spectacles were provided free at baseline, wear among those who could benefit was <40% at all but 2 centers (Guangzhou and Los Angeles). Conclusions: Prevalence of correctable NVI is greatest among persons of working age, and rates of correction are low in many settings, suggesting that strategies targeting the workplace may be needed.

c-Met inhibition in a HOXA9/Meis1 model of CN-AML

BACKGROUND: Hematopoiesis is a paradigm for developmental processes, hierarchically organized, with stem cells at its origin. Hematopoietic stem cells (HSCs) replenish progenitor and precursor cells of multiple lineages, which normally differentiate into short-lived mature circulating cells. Hematopoiesis has provided insight into the molecular basis of tissue homeostasis and malignancy. Malignant hematopoiesis, in particular acute myeloid leukemia (AML), results from impaired development or differentiation of HSCs and progenitors. Co-overexpression of HOX and TALE genes, particularly the HOXA cluster and MEIS1, is associated with AML. Clinically relevant models of AML are required to advance drug development for an aging patient cohort.

RESULTS: Molecular analysis identified altered gene, microRNA, and protein expression in HOXA9/Meis1 leukemic bone marrow compared to normal controls. A candidate drug screen identified the c-Met inhibitor SU11274 for further analysis. Altered cell cycle status, apoptosis, differentiation, and impaired colony formation were shown for SU11274 in AML cell lines and primary leukemic bone marrow.

CONCLUSIONS: The clonal HOXA9/Meis1 AML model is amenable to drug screening analysis. The data presented indicate that human AML cells respond in a similar manner to the HOXA9/Meis1 cells, indicating pre-clinical relevance of the mouse model.

Étude de la représentation du curé dans deux films québécois La petite Aurore l'enfant martyre (1952) et Aurore (2005)

Ce mémoire porte sur la représentation du curé dans les films La petite Aurore l'enfant martyre (Jean-Yves Bigras, 1952) et Aurore (Luc Dionne, 2005). L'objectif principal est d'identifier l'image que l'on présente du curé dans ces deux oeuvres. L'étude de cette représentation permet de cerner les discours portés par ces deux films à travers le personnage du curé et d'apprécier dans quelle mesure ces discours filmiques témoignent du caractère de la société québécoise à deux époques déterminées, soit les années 1950 et les années 2000. Inscrite dans le champ des études culturelles, la recherche se fonde sur quatre axes théoriques principaux : la représentation, l'interprétation, la mythologie et l'analyse filmique. Les travaux de Stuart Hall, d'Umberto Eco et de Roland Barthes constituent le cadre théorique. L'approche de l'analyse de contenu s'inspire des travaux de Laurence Bardin et l'analyse filmique, de ceux de Jean Mitry, d'Anne Goliot-Lété et de Francis Vanoye, entre autres. La procédure de recherche consiste dans le découpage des éléments constitutifs de chaque film en plans, séquences et extraits, de manière à déconstruire les récits filmiques et à faire émerger les facteurs signifiants susceptibles de permettre de reconstituer le sens à travers la reconstruction du rôle du curé et la caractérisation du personnage dans chacun des films. La démarche d'interprétation s'appuie sur une série de thèmes sous lesquels se classent, en opposition souvent, les attributs des deux personnages, comme l'apparence générale, l'intégration au milieu, l'intellectualité, la figure d'autorité, le conformisme et la responsabilité. L'hypothèse principale formulée dans le cadre de la problématique se trouve validée. La représentation du curé dans le film de 1952 offre une image idéalisée du « bon curé », laquelle est conforme au discours dominant de son époque de production. Dans le film de 2005, on délaisse plutôt l'image idéalisée pour revêtir le curé d'attributs négatifs et le rendre responsable, en grande partie, du drame vécu par Aurore. De plus, les trois hypothèses secondaires ont pu aussi être validées : la représentation du curé en 2005 est liée à une plus grande sensibilité au phénomène de la maltraitance des enfants et au besoin d'en identifier les responsables; le transfert de responsabilité vers le curé semble le reflet de reproches adressés par la société québécoise au clergé pour des fautes du passé et la représentation péjorative du curé de 2005, où l'on insiste sur son caractère froid et distant, ne choque plus personne. Porteuse de plusieurs mythes, dont certains rejoignent les fondements de l'identité québécoise, l'histoire d'Aurore fait partie intégrante du patrimoine culturel. Les relectures de cette triste affaire au fil des ans traduisent aussi les changements qui marquent la société québécoise, en particulier dans son rapport au clergé et à la religion.

La parole en action : dissensus sur les accommodements raisonnables lors des auditions en commission parlementaire au Québec (2010-2011)

La question du pluralisme religieux est au Québec, l’objet de désaccords et de variations dans son mode de régulation et ses instruments d’action publique. La consultation publique sur le projet loi n° 94, Loi établissant les balises encadrant les demandes d’accommodement dans l’Administration gouvernementale et dans certains établissements, est au cœur de ceux-ci. En se basant sur l’analyse des séances d’auditions publiques en commission parlementaire qui ont eu lieu au Québec entre mai 2010 et janvier 2011 sur le projet de loi n° 94, cette thèse vise à interroger les enjeux liés à la publicisation des prises de positions et de l’échange d’arguments entre différents acteurs. À partir d’une méthodologie par théorisation enracinée et d’un cadre conceptuel qui se rattache à la communication publique, cette thèse cherche à mettre en évidence quelques-unes des propriétés des interactions verbales et non verbales qui composent et incarnent cette activité délibérative. Elle approche ces interactions du point de vue de leur publicisation en s’appuyant sur deux principes : la participation publique en tant qu’un instant de la construction du problème public et l’audition publique en commission parlementaire comme maillon d’un réseau dialogique qui participe à la publicisation du désaccord sur les accommodements raisonnables. Mettant l’accent sur l’usage du langage (verbal, non verbal et para verbal), l’objectif de cette thèse est de mieux comprendre comment des groupes minoritaires et majoritaires, engagés dans une arène publique où les points de vue par rapport aux accommodements raisonnables sont confrontés et mis en visibilité, gèrent leur situation de parole publique. La démarche de recherche a combiné deux stratégies d’analyse : la première stratégie d’inspiration conversationnelle, qui observe chaque séquence comme objet indépendant, a permis de saisir le déroulement des séances d’audition en respectant le caractère séquentiel des tours de parole La deuxième stratégie reviens sur les principaux résultats de l’analyse des séances d’auditions pour valider les résultats et parvenir à la saturation théorique pour élaborer une modélisation. L’exploitation des données selon cette approche qualitative a abouti au repérage de trois dynamiques. La première fait état des contraintes discursives. La seconde met en évidence le rôle des dimensions motivationnelles et socioculturelles dans la construction des positionnements et dans l’adoption d’un registre polémique. La troisième souligne la portée de la parole publique en termes d’actualisation des rapports de pouvoir et de confirmation de son caractère polémique. La modélisation proposée par cette thèse représente le registre polémique comme un élément constitutif de l’engagement argumentatif des acteurs sociaux mais qui est considérablement enchâssé dans d’autres éléments contextuels et motivationnels qui vont orienter sa portée. En tant qu’elle est exprimée dans un site dialogique, la parole publique en situation d’audition publique en commission parlementaire est en mesure de créer de nouvelles intrigues et d’une possibilité de coexister dans le dissensus. Le principal apport de cette thèse est qu’elle propose une articulation, concrète et originale entre une approche de la parole publique en tant que révélatrice d’autre chose que d’elle-même (nécessaire à tout éclaircissement des points de vue dans cette controverse) et une approche de la parole publique en tant que performance conduisant à la transformation du monde social. D’où, le titre de la thèse : la parole en action. Mots clefs : parole publique, discours, arène publique, pluralisme religieux, accommodements raisonnables, controverses, dissensus, théorisation enracinée

Padrão de ativação de músculos do core abdominal e tilt pélvico no teste de extensão da anca, em indivíduos com e sem dor lombo- pélvica

Introdução: Os padrões de movimento podem sofrer alterações por atraso no timing de ativação e/ou modificações na sequência de recrutamento muscular, predispondo o indivíduo a disfunções, nomeadamente a dor lombo-pélvica. Objetivo: Investigar o timing e o padrão de ativação de músculos do core abdominal, durante o movimento de extensão da anca, do membro dominante, em indivíduos com e sem dor lombo- pélvica crónica inespecífica. Pretende-se, também, pesquisar a existência do padrão de ativação considerado “normal“ e verificar a relação entre o padrão de ativação e o tilt pélvico, em ambos os indivíduos. Métodos: Estudo transversal, com 64 estudantes universitários, divididos em dois grupos: 31 sem e 33 com dor lombo-pélvica. Através de eletromiografia de superfície foi recolhida a atividade muscular dos Eretores da Espinha ipsilateral e contralateral, Glúteo Máximo e Bicípite Femoral ipsilaterais. Foi analisado o timing de ativação muscular e as respetivas ordens de ativação. Adicionalmente foi medido o tilt pélvico. Resultados: O grupo com dor lombo-pélvica apresentou um atraso significativo no timing de ativação dos músculos Glúteo Máximo ipsilateral (t=-3,171;p=0,002) e Bicípite Femoral ipsilateral (t=-2,092;p=0,041), em comparação com o grupo sem dor. Verificou-se uma associação significativa entre as 5 ordens de ativação mais frequentes e a presença de dor lombo-pélvica (xf2=11,54;p=0,015). A ordem de ativação "normal" – Glúteo Máximo ipsilateral>Bicípite Femoral ipsilateral>Eretor da Espinha contralateral>Eretor da Espinha ipsilateral – não foi utilizada. Verificou-se que o Bicípite Femoral ipsilateral foi maioritariamente o primeiro a ativar-se e o Glúteo Máximo ipsilateral o último em ambos os grupos. Verificou-se um tilt pélvico significativamente superior nos indivíduos que ativam primeiro o Bicípite Femoral ipsilateral nos grupos com (U=51;p=0,001) e sem dor (U=41p=0,001). Conclusão: Os indivíduos com dor lombo-pélvica apresentaram um atraso no timing de ativação dos músculos do core abdominal. Os resultados parecem refutar a ordem de ativação "normal" que tem sido proposta. Não foi possível apoiar nem contestar a teoria de que um atraso na ativação do Glúteo Máximo está associado com dor lombo-pélvica.